Carfilzomib?associated pulmonary arterial hypertension in multiple myeloma

Drug-induced pulmonary arterial hypertension (PAH) is constantly evolving as new drugs are developed. Carfilzomib a recently approved therapy for relapsed and refractory multiple myeloma. While it has been associated with cardiovascular adverse events, such ischemic heart disease failure, PAH not well-described side effect. We present two patients who developed initiation of carfilzomib. They both initially presented severe dyspnea, had elevated right ventricular systolic pressure on transthoracic echocardiography ultimately underwent catheterization. With discontinuation carfilzomib, improvement in hemodynamics. However, one patient required PAH-targeted therapies worsening function again despite permanent It important to recognize the association between carfilzomib PAH. Echocardiography can be an initial screening tool. from may reversible, especially if diagnosed early; however, extended follow-up essential.